Universitair Medisch Centrum Groningen
- Address
- lock Available on a paid plan
Cardiovascular Research
At Universitair Medisch Centrum Groningen, cardiovascular disease studies focus on improving care for people at risk of or recovering from acute myocardial infarction. The trials are designed to test new approaches that may help patients respond faster to symptoms and reduce the chance of future heart events.
- Testing a self-administered treatment approach for suspected acute myocardial infarction
- Evaluating better options for preventing recurrent cardiac events
- Advancing treatment strategies in cardiology
These studies aim to strengthen emergency response and improve outcomes for patients with serious heart disease.
Hematology and Blood Cancer Research
The site is active in hematologic malignancies research, with trials involving acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, diffuse large B-cell lymphoma, and related marrow disorders. The main goal is to assess whether new treatment combinations can improve remission rates, disease control, and long-term survival.
- Studying new treatment strategies for acute myeloid leukemia with genetic mutations
- Evaluating therapies for chronic lymphocytic leukemia and residual disease
- Testing novel regimens for Hodgkin lymphoma and aggressive lymphomas
These trials reflect a strong focus on refining cancer treatment and helping more patients reach deeper, more durable responses.
Solid Tumor and Oncology Studies
Oncology research at this hospital includes studies in renal cell carcinoma, gastrointestinal stromal tumor, and neuroendocrine tumours. The trials are aimed at comparing treatment effectiveness and finding better ways to control advanced or metastatic disease.
- Comparing new immunotherapy combinations with standard cancer treatment
- Assessing targeted therapy options for gastrointestinal stromal tumor
- Exploring treatment continuation strategies for neuroendocrine tumours
This research supports more personalized cancer care by identifying therapies that may offer better disease control and longer survival.
Reproductive and Urogenital Health
Clinical trials in reproductive and urinary physiological phenomena and female urogenital diseases address unexplained subfertility and infertility. The research is focused on improving the chances of pregnancy and evaluating supportive treatments used alongside fertility care.
- Assessing whether added support can improve live birth rates
- Studying treatment approaches for couples with unexplained subfertility
- Evaluating practical ways to make fertility care more effective
These studies aim to provide clearer guidance for patients and clinicians working to improve fertility outcomes.
Eye and Transplant Research
The ophthalmology and transplant-related work includes trials in corneal transplantation and Descemet's Membrane Endothelial Keratoplasty. Researchers are examining ways to improve graft success, protect eye health, and reduce treatment-related complications.
- Evaluating better immune suppression after corneal transplantation
- Testing strategies to preserve corneal cells and eye pressure control
- Improving recovery after Descemet's Membrane Endothelial Keratoplasty
These studies support safer and more durable outcomes for patients undergoing corneal surgery.
Rare Disease and Skin Research
Research in skin and connective tissue diseases includes studies for recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The trials are focused on assessing the safety and potential benefit of new therapies for these rare, serious conditions.
- Testing new treatment options for epidermolysis bullosa
- Evaluating approaches that may improve skin stability and healing
- Building evidence for care in rare inherited disorders
This work reflects an important effort to expand treatment options for patients with limited existing therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 40 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Academisch Ziekenhuis Maastricht1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitair Medisch Centrum Groningen
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 40 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sunitinib | 3 | Unknown | 2014-11-19 | 2023-06-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.